Results 81 to 90 of about 143,360 (302)

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Antiplatelet therapy for secondary prevention of coronary artery disease. [PDF]

, 2014
The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core   +1 more source

Patient preferences for medicines information in cardiovascular disease and the influence of unmet needs on medication adherence: A cross‐sectional study

British Journal of Clinical Pharmacology, EarlyView.
A survey of 313 Australians with cardiovascular disease found strong preferences for digitally delivered medicine information. Half of participants reported unmet information needs related to their medicines, which were associated with lower medication adherence.
Lachlan L. Dalli, Susie Cartledge, Caroline Trin, Zuhayr Alji, Justine Causing, Monique F. Kilkenny, Antonia Arfaras, Stella Talic   +7 more
wiley   +1 more source

Editorial: Women in thrombosis

Frontiers in Cardiovascular Medicine, 2023
Claire S. Whyte, Marina Panova-Noeva
doaj   +1 more source

Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tumors

Gut and Liver, 2018
Background/AimsCurrent guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding.Methods : Gastric ESD cases with ...
Sooyeon Oh, Sang Gyun Kim, Jung Kim, Ji Min Choi, Joo Hyun Lim, Hyo-Joon Yang, Jae Yong Park, Seung Jun Han, Jue Lie Kim, Hyunsoo Chung, Hyun Chae Jung   +10 more
doaj   +1 more source

Antiplatelet combinations for prevention of atherothrombotic events

, 2011
Mario Bollat,i Fiorenzo Gaita, Matteo AnselminoDepartment of Internal Medicine, Division of Cardiology, University of Torino, ItalyAbstract: Antiplatelet therapy plays a fundamental role in reducing atherothrombotic events by several pathways.
Anselmino M, Bollati M, Gaita F
core  

Preclinical Serial Assessment of Virtual Physiology After Implantation of a Novel Endoluminal Resorbable Fibrillated Scaffold

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The resorbable fibrillated scaffold (RFS) is a novel electrospun, polylactide‐based endoluminal scaffold developed for peripheral arterial applications. Its porous microfibre architecture is intended to support host cell infiltration and vascular restoration.
Kotaro Miyashita, Lucas Hatzikostas, Emiliano Bianchini, Milosz Dziarmaga, Chun‐Ting Shih, Jouke Dijkstra, Eric K. W. Poon, Bart Sanders, Golo von Basum, Rick de Vries, Kim van Noort, Marc van Sambeek, Jos C. van den Berg, Albert Chinhenzva, Scot Garg, Yoshinobu Onuma, Patrick W. Serruys   +16 more
wiley   +1 more source

Drug‐Coated Balloon‐Based Strategy for De Novo Coronary Artery Disease Across Complex and High‐Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI).
Dong Oh Kang, Sunwon Kim, Ae‐Young Her, Eun‐Seok Shin   +3 more
wiley   +1 more source

NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN

Российский кардиологический журнал, 2015
Antithrombotic treatment of acute coronary syndrome leads to much better outcomes of the disease. The article focuses on the arguments and evidence for the addition to antiplatelet drugs the rivaroxaban 2,5 mg two times per day for secondary prevention ...
I. N. Bokarev, A. V. Golub
doaj   +1 more source

Antiplatelet agents and proton pump inhibitors – personalizing treatment

, 2010
Eugene Lin, Rajiv Padmanabhan, Majaz MoonisDepartment of Neurology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USAIntroduction: Antiplatelet therapy remains one of the cornerstones in the ...
Eugene Lin, Rajiv Padmanabhan, Majaz Moonis   +2 more
core